University of Illinois Chicago scientists have redesigned a treatment for the most common pediatric leukemia to eliminate its severe side effects, like blood clots and liver damage. If approved, the new drug may be tolerated by a broader range of leukemia patients and even be used to treat other cancers. The team led by UIC’s Arnon Lavie created… Continue reading UIC scientists redesign asparaginase to minimize leukemia treatment side effects
Tag: Leukemia and Lymphoma
Successful T cell immune reconstitution following Cultured Thymus Tissue Implantation (CTTI) in children with congenital athymia who received Hematopoietic Stem Cell Transplant (HSCT)
Alternative Algorithm For Rapid E.coli L-asparaginase Desensitization Via Intramuscular Administration In Children With Acute Lymphoblastic Leukemia: A Single-Center Experience
Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma
Bispecific antibodies (BsAb) have emerged as a leading treatment modality in patients suffering from B-cell non-Hodgkin’s lymphoma (B-NHL). However, treatment failure is common and may potentially be attributed to pre-existing or emerging T-cell exhaustion. CD39 catalyzes—together with CD73—the hydrolysis of immunogenic ATP into immunosuppressive adenosine and thus actively promotes an immunosuppressive micromilieu. Previously, we and… Continue reading Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma
Discovery of selective, metabolically stable pyrazole-based FLT3 inhibitors for the treatment of Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is the most prevalent form of acute leukemia in adults, representing a substantial medical need, as the standard of care has not changed for the past two decades, and long-term outcome remains dismal for a large fraction of patients. Approximately 30% of AMLs carry activating mutations of the FLT3 kinase. Unfortunately,… Continue reading Discovery of selective, metabolically stable pyrazole-based FLT3 inhibitors for the treatment of Acute Myeloid Leukemia
Neomorphic leukemia-derived mutations in the TET2 enzyme induce genome instability via a substrate shift from 5-methylcytosine to thymine
Plasma membrane-coated nanoparticles and membrane vesicles to orchestrate multimodal antitumor immunity
Background A number of immunotherapeutic approaches have been developed and are entering the clinic. Bispecific antibodies (BsAbs) are one of these modalities and induce robust efficacy by endogenous T cells in several hematological malignancies. However, most of the treated patients experience only a temporary benefit. Currently available BsAbs provide only anti-CD3 antibody-mediated T-cell stimulation, but… Continue reading Plasma membrane-coated nanoparticles and membrane vesicles to orchestrate multimodal antitumor immunity
Comments on The Study of Correlation Between Progression-Free and Overall Survival in Patients with Hodgkin Lymphoma
Although the study by Bröckelmann et al. examining the correlation between progression-free survival (PFS) and overall survival (OS) in patients with Hodgkin lymphoma (HL) using individual patient data from the GHSG trials shed light on the predictive value of PFS for OS,1 there are several limitations needed to further clarify or improve.
Transforming paediatric AML trials: from failing one-size-fits-all methods to precision oncology
Paediatric acute myeloid leukaemia (AML) highlights the challenges of drug development for rare diseases, in which limited patient numbers and substantial heterogeneity hinder progress. Traditional one-size-fits-all randomized trials are ineffective. Nonetheless, tailored therapies and biomarker-driven studies can improve outcomes and transform the treatment of paediatric patients with AML and potentially other rare cancers. This is… Continue reading Transforming paediatric AML trials: from failing one-size-fits-all methods to precision oncology
Immune environment found to influence success of leukemia immunotherapy
A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics made a pivotal discovery in the field of cancer immunotherapy. In a paper published today in Science Immunology, the team identified a specific population of immune cells that play a critical role in successful treatment of relapsed acute myeloid leukemia (AML). This work was in collaboration with… Continue reading Immune environment found to influence success of leukemia immunotherapy